Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices

Iveson, 2019, Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC), J. Clin. Oncol., 37, 3501, 10.1200/JCO.2019.37.15_suppl.3501 Grothey, 2018, Duration of Adjuvant Chemotherapy for Stage III Colon Cancer, N. Engl. J. Med., 378, 1177, 10.1056/NEJMoa1713709 Sobrero, 2020, J. Clin. Oncol., 38, 4004, 10.1200/JCO.2020.38.15_suppl.4004 André, 2020, Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials, Lancet Oncol., 21, 1620, 10.1016/S1470-2045(20)30527-1 Iveson, 2021, Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer, J. Clin. Oncol., 39, 631, 10.1200/JCO.20.01330 Roseweir, 2020, Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer, J. Pathol. Clin. Res., 6, 283, 10.1002/cjp2.171 Alexander, 2021, The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer, Br. J. Cancer, 124, 786, 10.1038/s41416-020-01168-x Iveson, 2018, 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial, The Lancet. Oncology., 19, 562, 10.1016/S1470-2045(18)30093-7 Sobrero, 2018, The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?, Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol., 29, 1099, 10.1093/annonc/mdy064 Marshall, 2017, How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer, Colorectal Cancer, 6, 107, 10.2217/crc-2017-0019 Fuerst, 2018, Debate: 3 or 6 Months Adjuvant Therapy for Stage III Colon Cancer, Oncology Times, 40 Ouali, 2019, Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey, Ann. Oncol., 30, v210, 10.1093/annonc/mdz246.032 Yu I.S., Pereira A.A.L., Lee M., et al. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. The Oncologist. 2019. Muzny, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 Kawakami, 2015, Microsatellite instability testing and its role in the management of colorectal cancer, Curr. Treat. Options Oncol., 16, 30, 10.1007/s11864-015-0348-2 Glover, 2014, Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes, BMC Med., 12, 99, 10.1186/1741-7015-12-99 Robles-Zurita, 2018, SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer, Br. J. Cancer, 119, 1332, 10.1038/s41416-018-0319-z Tournigand, 2012, J. Clin. Oncol., 30, 3353, 10.1200/JCO.2012.42.5645 Yothers, 2011, Oxaliplatin As Adjuvant Therapy for Colon Cancer: updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses, J. Clin. Oncol., 29, 3768, 10.1200/JCO.2011.36.4539 Taylor, 2020, Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: can a regional intervention promote national change?, Int. J. Cancer Meyers, 2017, Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: a Cancer Care Ontario Systematic Review, Clin. Oncol., 29, 459, 10.1016/j.clon.2017.03.001 Haller, 2015, Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials, Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol., 26, 715, 10.1093/annonc/mdv003 McCleary, 2013, Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: findings From the ACCENT Database, J. Clin. Oncol., 31, 2600, 10.1200/JCO.2013.49.6638 Salem, 2020, Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol., 31, 480, 10.1016/j.annonc.2019.12.007 Excellence NIfHaC. Colorectal cancer NICE guideline [NG151] Published date: 29 January 2020 2020. Iveson, 2021, The Early Impact of the IDEA Collaboration Results: how the Results Changed Prescribing Practice, JNCI Cancer Spectrum, 10.1093/jncics/pkab043 Chau, 2005, A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer, Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol., 16, 549, 10.1093/annonc/mdi116 Excellence NIfHaC. COVID-19 rapid guideline: delivery of systemic anticancer treatments 2020. Morris E.J.A., Goldacre R., Spata E., et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. The Lancet Gastroenterology & Hepatology. Sobrero, 2020, A new prognostic and predictive tool for shared decision making in stage III colon cancer, Eur. J. Cancer, 138, 182, 10.1016/j.ejca.2020.07.031